KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to 13.32%.

  • Charles River Laboratories International's EBITDA Margin rose 16900.0% to 13.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.5%, marking a year-over-year decrease of 95000.0%. This contributed to the annual value of 5.61% for FY2024, which is 93300.0% down from last year.
  • Charles River Laboratories International's EBITDA Margin amounted to 13.32% in Q3 2025, which was up 16900.0% from 9.7% recorded in Q2 2025.
  • In the past 5 years, Charles River Laboratories International's EBITDA Margin registered a high of 19.26% during Q2 2022, and its lowest value of 16.73% during Q4 2024.
  • Its 5-year average for EBITDA Margin is 12.88%, with a median of 14.89% in 2022.
  • As far as peak fluctuations go, Charles River Laboratories International's EBITDA Margin skyrocketed by 42200bps in 2022, and later tumbled by -298400bps in 2024.
  • Over the past 5 years, Charles River Laboratories International's EBITDA Margin (Quarter) stood at 19.09% in 2021, then decreased by -22bps to 14.89% in 2022, then decreased by -12bps to 13.12% in 2023, then plummeted by -228bps to 16.73% in 2024, then soared by 180bps to 13.32% in 2025.
  • Its EBITDA Margin was 13.32% in Q3 2025, compared to 9.7% in Q2 2025 and 7.59% in Q1 2025.